Literature DB >> 22585694

Influence of sex on the survival of patients with esophageal cancer.

Pierre Bohanes1, Dongyun Yang, Ruchika S Chhibar, Melissa J Labonte, Thomas Winder, Yan Ning, Armin Gerger, Léonor Benhaim, David Paez, Takeru Wakatsuki, Fotios Loupakis, Rita El-Khoueiry, Wu Zhang, Heinz-Josef Lenz.   

Abstract

PURPOSE: The prognostic value of sex for esophageal cancer survival is currently unclear, and growing data suggest that hormonal influences may account for incidence disparities between men and women. Therefore, moving from the hypothesis that hormones could affect the prognosis of patients with esophageal cancer, we investigated the primary hypothesis that sex is associated with survival and the secondary hypotheses that the relationship between sex and survival depends, at least in part, on age, histology, and race/ethnicity. PATIENTS AND METHODS: By using the SEER databases from 1973 to 2007, we identified 13,603 patients (34%) with metastatic esophageal cancer (MEC) and 26,848 patients (66%) with locoregional esophageal cancer (LEC). Cox proportional hazards model for competing risks were used for analyses.
RESULTS: In the multivariate analysis, women had longer esophageal cancer-specific survival (ECSS) than men in both MEC (hazard ratio [HR], 0.949; 95% CI, 0.905 to 0.995; P = .029) and LEC (HR, 0.920; 95% CI, 0.886 to 0.955; P < .001) cohorts. When age and histology were accounted for, there was no difference for ECSS between men and women with adenocarcinoma. In contrast, women younger than age 55 years (HR, 0.896; 95% CI, 0.792 to 1.014; P = .081) and those age 55 years or older (HR, 0.905; 95% CI, 0.862 to 0.950; P < .001) with squamous cell LEC had longer ECSS than men. In the squamous cell MEC cohort, only women younger than age 55 years had longer ECSS (HR, 0.823; 95% CI, 0.708 to 0.957; P = .011) than men.
CONCLUSION: Sex is an independent prognostic factor for patients with LEC or MEC. As secondary hypotheses, in comparison with men, women age 55 years or older with squamous cell LEC and women younger than age 55 years with squamous cell MEC have a significantly better outcome. These last two findings need further validation.

Entities:  

Mesh:

Year:  2012        PMID: 22585694      PMCID: PMC3397720          DOI: 10.1200/JCO.2011.38.8751

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  47 in total

1.  Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus.

Authors:  T Tihan; J W Harmon; X Wan; Z Younes; P Nass; K L Duncan; M D Duncan
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  Assessment of immunohistochemistry for p16INK4 and high-risk HPV DNA by in situ hybridization in esophageal squamous cell carcinoma.

Authors:  Sajjad M Malik; Daniel T Nevin; Sidney Cohen; Jennifer L Hunt; Juan P Palazzo
Journal:  Int J Surg Pathol       Date:  2010-11-17       Impact factor: 1.271

4.  High-risk human papillomavirus in esophageal squamous cell carcinoma.

Authors:  Annika Antonsson; Derek J Nancarrow; Ian S Brown; Adele C Green; Paul A Drew; David I Watson; Nicholas K Hayward; David C Whiteman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08       Impact factor: 4.254

5.  Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus.

Authors:  Hulya Akgun; Juan Lechago; Mamoun Younes
Journal:  Anticancer Res       Date:  2002 May-Jun       Impact factor: 2.480

6.  Impact of postoperative radiation after esophagectomy for esophageal cancer.

Authors:  David Schreiber; Justin Rineer; Dan Vongtama; Angela Wortham; Peter Han; David Schwartz; Kwang Choi; Marvin Rotman
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609

Review 7.  Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus.

Authors:  W O Rebecca; M A Richard
Journal:  Cochrane Database Syst Rev       Date:  2003

8.  The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma.

Authors:  Naveenraj Solomon; Ying Zhuge; Michael Cheung; Dido Franceschi; Leonidas G Koniaris
Journal:  Ann Surg Oncol       Date:  2009-12-02       Impact factor: 5.344

9.  Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.

Authors:  Daniel King Hung Tong; Simon Law; Dora Lai Wan Kwong; Kwok Wah Chan; Alfred King Yin Lam; Kam Ho Wong
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

Review 10.  HPV infections and oesophageal cancer.

Authors:  K J Syrjänen
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

View more
  53 in total

Review 1.  Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed?

Authors:  Costanza Chiapponi; Felix Berlth; Patrick S Plum; Christopher Betzler; Dirk L Stippel; Felix Popp; Christiane J Bruns
Journal:  Visc Med       Date:  2017-02-15

2.  Associations between ABO blood groups and biochemical recurrence after radical prostatectomy.

Authors:  Yoshio Ohno; Makoto Ohori; Jun Nakashima; Hidenori Okubo; Naoya Satake; Issei Takizawa; Takeshi Hashimoto; Riu Hamada; Yoshihiro Nakagami; Kunihiko Yoshioka; Masaaki Tachibana
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Younger women have a better prognosis among patients with esophageal squamous cell carcinoma after esophagectomy.

Authors:  Xiao-Dong Su; Xu Zhang; Hao-Jun Xie; Peng Lin; Lanjun Zhang; Tiehua Rong
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

4.  Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Authors:  L N Mathieu; N F Kanarek; H-L Tsai; C M Rudin; M V Brock
Journal:  Dis Esophagus       Date:  2013-10-07       Impact factor: 3.429

5.  Downregulated miR-486-5p acts as a tumor suppressor in esophageal squamous cell carcinoma.

Authors:  Yunfeng Yi; Xiujuan Lu; Jianming Chen; Changjie Jiao; Jing Zhong; Zhiming Song; Xiaoping Yu; Baoli Lin
Journal:  Exp Ther Med       Date:  2016-10-05       Impact factor: 2.447

Review 6.  Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.

Authors:  Hugo Ford; Ioannis Gounaris
Journal:  Therap Adv Gastroenterol       Date:  2015-07       Impact factor: 4.409

7.  Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Yoshifumi Baba; Masayuki Watanabe; Satoshi Ida; Takatsugu Ishimoto; Ryuichi Karashima; Shiro Iwagami; Yu Imamura; Yasuo Sakamoto; Yuji Miyamoto; Hideo Baba
Journal:  Surg Today       Date:  2014-07-06       Impact factor: 2.549

8.  Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy.

Authors:  Yun Chen; Zhen Zhang; Guoliang Jiang; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 9.  Social group disparities in the incidence and prognosis of oesophageal cancer.

Authors:  Shao-Hua Xie; Jesper Lagergren
Journal:  United European Gastroenterol J       Date:  2018-01-10       Impact factor: 4.623

10.  Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Authors:  Yu Sunakawa; Takeru Wakatsuki; Dongyun Yang; Wu Zhang; Yan Ning; Sebastian Stintzing; Stefan Stremitzer; Shinichi Yamauchi; Ana Sebio; Rita El-khoueiry; Syma Iqbal; Afsaneh Barzi; Armin Gerger; Michael Stotz; Mizutomo Azuma; Masahiko Watanabe; Wasaburo Koizumi; Heinz-Josef Lenz
Journal:  Pharmacogenet Genomics       Date:  2014-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.